Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2021 Earnings Conference Call November 9, 2020 5:00 PM ET Company Participants Scott Gleason – Senior Vice President of Investor Relations and Corporate Strategy Paul Diaz – President and Chief Executive Officer Bryan Riggsbee – Chief Financial Officer Conference Call Participants Doug Schenkel – Cowen Steve Unger – Needham Tycho Peterson – JPMorgan Puneet Souda – SVB Leerink Derik de Bruin – Bank of America Jack Meehan – Nephron Operator Greetings and welcome to the M ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-Q _________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 _________________ ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2020 Earnings Call August 13, 2020 4:30 PM ET Executives Scott Gleason - Myriad Genetics, Inc. R. Bryan Riggsbee - Myriad Genetics, Inc. Paul J. Diaz - Myriad Genetics, Inc. Analysts Sung-Ji Nam - BTIG LLC Doug Schenkel - Cowen and Company, LLC Tycho W. Peterson - JPMorgan Securities LLC Stephen Unger - Needham & Co. LLC Puneet Souda - SVB Leerink LLC Derik de Bruin - Bank of America Merrill Lynch Brandon Couillard - Jefferies LLC Jack Meehan - Nephron Research Operato ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------|----------------------------------------------|-----------------------------|---- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 87-0494517 (State or other jurisdicti ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2020 Results Conference Call May 5, 2020 4:30 PM ET Company Participants Scott Gleason - Vice President-Investor Relations Bryan Riggsbee - Interim President and Chief Executive Officer Conference Call Participants Westley Dupray - SVB Leerink Ivy Ma - Bank of America Operator Greetings, and welcome to the Myriad Genetics Third Quarter 2020 Financial Earnings Call. During the presentation, all participants will be in a listen-only mode and afterwards, we will conduct a ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2020 Earnings Conference Call February 6, 2020 4:30 PM ET Company Participants Scott Gleason - Vice President-Investor Relations Bryan Riggsbee - Interim President and Chief Executive Officer Conference Call Participants Bill Quirk - Piper Jaffray Doug Schenkel - Cowen and Company Tycho Peterson - JPMorgan Sung Ji Nam - BTIG, LLC Ivy Ma - Bank of America Puneet Souda - SVB Leerink Jack Meehan - Barclays Operator Greetings, and welcome to the Myriad Genetics Second Quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 87-0494517 (State or other jurisd ...